.png?width=137&height=33&name=footer-logo%20(1).png "logo.png"){kind=small}
I am excited to share that one of our recent papers written in collaboration with EMD Serono, Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab, has been recognized as one of the most cited in its publication last year. Reflecting on this achievement, I wanted to provide some insights into why I believe this paper resonated so strongly with the pharmacometrics community and became such a valuable resource.
